Market revenue in 2023 | USD 7.9 million |
Market revenue in 2030 | USD 17.1 million |
Growth rate | 11.7% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 59.49% in 2023. Horizon Databook has segmented the Kuwait head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Kuwait is one of the fastest-growing countries in the MEA due to its increasing exports and growing economy. With major advancements in its healthcare infrastructure, the country is addressing the growing prevalence of infectious, chronic, and lifestyle-associated diseases.
Therefore, the rising prevalence of target diseases in the country is a major factor driving the market. The government of Kuwait’s Vision 2030 initiative involves rapid infrastructure expansion of the healthcare system.
The government is also planning to make the Kuwait Cancer Control Center the largest cancer center in the Middle East; it will address the large need for cancer screening and therapeutics. Kuwait is increasingly emphasizing early diagnosis and screening for a better treatment outlook.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account